scispace - formally typeset
Open AccessJournal ArticleDOI

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.

TLDR
This work investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails.
Abstract
Antibodies targeting the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present a promising approach to combat the coronavirus disease 2019 (COVID-19) pandemic; however, concerns remain that mutations can yield antibody resistance. We investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails. These antibodies remain effective against spike variants that have arisen in the human population. However, novel spike mutants rapidly appeared after in vitro passaging in the presence of individual antibodies, resulting in loss of neutralization; such escape also occurred with combinations of antibodies binding diverse but overlapping regions of the spike protein. Escape mutants were not generated after treatment with a noncompeting antibody cocktail.

read more

Citations
More filters
Journal ArticleDOI

A neutralizing-protective supersite of human monoclonal antibodies for yellow fever virus

TL;DR: In this paper , the authors isolated eight human monoclonal antibodies that neutralize YFV infection in a mouse model, and two of them (YD6 and YD73) were ultra-potent and conferred complete protection against the lethal challenge of the yellow fever virus as both prophylactics and therapeutics.
Journal ArticleDOI

Don't worry! The next generation would be more resistant to SARS-CoV-2.

TL;DR: This letter addresses concerns regarding the paper “SARS‐CoV‐2 will continue to circulate in the human popu‐ lation: an opinion from the point of view of the virus‐host relationship” published recently in the Inflammation Research.
Journal ArticleDOI

How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?

TL;DR: In this paper , the authors highlight the role of humoral immunity in the host defense against SARS-CoV-2, with a focus on highly neutralizing antibodies, and advocate that beyond antibody responses, the development of a robust cellular immunity is of utmost importance for promoting immune memory and limiting disease severity, especially in case of re-infection by variant viruses.
Journal ArticleDOI

ORFeome Phage Display Reveals a Major Immunogenic Epitope on the S2 Subdomain of SARS-CoV-2 Spike Protein

TL;DR: An ORFeome phage display library for the SARS-CoV-2 genome was constructed and the most prominent epitope captured represented parts of the fusion peptide (FP) of the spike, which may provide an advantage in the fight against future virus variants.
Journal ArticleDOI

Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant

TL;DR: In this article , the authors evaluated the clinical efficacy of casirivimab-imdevimab in patients with COVID-19 Delta variant in Japan and showed that the combination antibody treatment is associated with reduced rates of requiring oxygen therapy among high-risk patients.
References
More filters
Journal ArticleDOI

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

TL;DR: Cryo–electron microscopy structures of full-length human ACE2 in the presence of the neutral amino acid transporter B0AT1 with or without the receptor binding domain (RBD) of the surface spike glycoprotein of SARS-CoV-2 are presented, providing important insights into the molecular basis for coronavirus recognition and infection.
Journal ArticleDOI

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.

TL;DR: The crystal structure of the C-terminal domain of SARS-CoV-2 (SARS- coV- 2-CTD) spike (S) protein in complex with human ACE2 (hACE2) is presented, which reveals a hACE2-binding mode similar overall to that observed for SARS -CoV.
Journal ArticleDOI

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.

TL;DR: Several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which was identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS- coV) in 2003, and one antibody (named S309) potently neutralization, which may limit the emergence of neutralization-escape mutants.
Related Papers (5)